The stock of ImmunityBio Inc (NASDAQ:IBRX) last traded at $1.80, up 25.87% from the previous session.
IBRX stock price is now 14.97% away from the 50-day moving average and -28.43% away from the 200-day moving average. The market capitalization of the company currently stands at $1.20B.
With the price target reduced from $10 to $4, Piper Sandler Downgraded its rating from Overweight to Neutral for ImmunityBio Inc (NASDAQ: IBRX).
In other news, BLASZYK MICHAEL D, Director bought 71,915 shares of the company’s stock on Jun 05. The stock was bought for $198,023 at an average price of $2.75. Upon completion of the transaction, the Director now directly owns 71,915 shares in the company, valued at $0.13 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 02, Director Brennan John Owen bought 25,000 shares of the business’s stock. A total of $70,700 was incurred on buying the stock at an average price of $2.83. This leaves the insider owning 25,000 shares of the company worth $45000.0. Insiders disposed of 46,465 shares of company stock worth roughly $83637.0 over the past 1 year. A total of 98.04% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in IBRX stock. A new stake in ImmunityBio Inc shares was purchased by SG AMERICAS SECURITIES, LLC during the first quarter worth $61,000. KESTRA ADVISORY SERVICES, LLC invested $48,000 in shares of IBRX during the first quarter. In the first quarter, JUMP FINANCIAL, LLC acquired a new stake in ImmunityBio Inc valued at approximately $41,000. AMERIPRISE FINANCIAL INC acquired a new stake in IBRX for approximately $40,000. WESTERN WEALTH MANAGEMENT, LLC purchased a new stake in IBRX valued at around $37,000 in the second quarter.
With an opening price of $1.4700 on Tuesday morning, ImmunityBio Inc (NASDAQ: IBRX) set off the trading day. During the past 12 months, ImmunityBio Inc has had a low of $1.21 and a high of $7.10. The fifty day moving average price for IBRX is $1.5646 and a two-hundred day moving average price translates $2.5024 for the stock.
The latest earnings results from ImmunityBio Inc (NASDAQ: IBRX) was released for Jun, 2023. According to the Biotechnology Company, earnings per share came in at -$0.32, missing analysts’ expectations of -$0.23 by -0.09. This compares to -$0.24 EPS in the same period last year. The company reported revenue of $41000.0 for the quarter, compared to $35000.0 a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 17.14 percent. For the current quarter, analysts expect IBRX to generate $20k in revenue.
ImmunityBio Inc(IBRX) Company Profile
ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases in the United States and Europe. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine technologies, toll-Like receptor activating adjuvants, natural killer cells, and damage-associated molecular patterns inducers. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute and Amyris, Inc.; and license agreements with LadRx Corporation, GlobeImmune, Inc., Access to Advanced Health Institute, 3M Innovative Properties Company, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company is based in San Diego, California.
